{
    "Clinical Trial ID": "NCT00454532",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Level 1",
        "10g/day",
        "INTERVENTION 2: ",
        "  Level 2",
        "20g/day"
    ],
    "Eligibility": [
        "Key Inclusion Criteria:",
        "  Women 18 years or older",
        "  Histologically confirmed breast cancer",
        "  Clinical evidence of metastatic (stage IV) metastasis (other than bone metastasis)",
        "  Availability of estrogen and progesterone receptor status",
        "  At least one measurable disease site defined by RECIST criteria, 30 days prior to study therapy",
        "  For the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. For the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer",
        "  Life expectancy  12 weeks",
        "  Eastern Cooperative Oncology Group performance status 2",
        "  Women of child bearing potential must agree to 2 forms of contraception during the course of the trial.",
        "  Key Exclusion Criteria:",
        "  Inability to understand/unwillingness to sign a written informed consent",
        "  Any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator",
        "  Currently using an investigational agent",
        "  Clinically significant gastrointestinal abnormalities",
        "  Currently using coumadin at therapeutic doses or within 2 weeks of taking study medication",
        "  Concurrent palliative radiation or anti-cancer treatment",
        "  Women who report pregnancy, are breast-feeding or have a positive pregnancy test"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Toxicity Based Upon Adverse Events Classifed by the NCI Common Terminology Criteria Version 3 (Phase 1)",
        "  Dose-Limiting Toxicities graded according to Common Terminology Criteria for Adverse Events, version 3.0",
        "  Time frame: Monthly",
        "Results 1: ",
        "  Arm/Group Title: Level 1",
        "  Arm/Group Description: 10g/day",
        "  Overall Number of Participants Analyzed: 11",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Elevated AST: 1",
        "  Diarrhea: 0",
        "  Fatigue: 0",
        "Pain-rib cage: 0",
        "Results 2: ",
        "  Arm/Group Title: Level 2",
        "  Arm/Group Description: 20g/day",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Elevated AST: 0",
        "  Diarrhea: 1",
        "  Fatigue: 1",
        "Pain-rib cage: 0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/11 (45.45%)",
        "  Hemorrhage, GI-abdomen NOS 21/11 (9.09%)",
        "  Pain-liver 21/11 (9.09%)",
        "  Infection-ulcer 20/11 (0.00%)",
        "  Hemoglobin 20/11 (0.00%)",
        "  Hypoglycemia 20/11 (0.00%)",
        "  Pain-rib cage due to vomiting 20/11 (0.00%)",
        "  Obstruction-gu ureter 1/11 (9.09%)",
        "  Hemorrhage gu-bladder 21/11 (9.09%)",
        "  Pain-breast 21/11 (9.09%)",
        "  Pleural effusion 22/11 (18.18%)",
        "Adverse Events 2:",
        "  Total: 0/6 (0.00%)",
        "  Hemorrhage, GI-abdomen NOS 20/6 (0.00%)",
        "  Pain-liver 20/6 (0.00%)",
        "  Infection-ulcer 20/6 (0.00%)",
        "  Hemoglobin 20/6 (0.00%)",
        "  Hypoglycemia 20/6 (0.00%)",
        "  Pain-rib cage due to vomiting 20/6 (0.00%)",
        "  Obstruction-gu ureter 0/6 (0.00%)",
        "  Hemorrhage gu-bladder 20/6 (0.00%)",
        "  Pain-breast 20/6 (0.00%)",
        "  Pleural effusion 20/6 (0.00%)"
    ]
}